Chromosome abnormalities at onset of complete remission are

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance) by Christian Niederwieser, Deedra Nicolet, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Jessica Kohlschmidt, Richard M. Stone, John C. Byrd, Krzysztof Mrózek, and Clara D. Bloomfield haematol Volume 101(12): 1516 -1523 November 30, 2016 © 2016 by Ferrata Storti Foundation

Overview of the study design. Christian Niederwieser et al. Haematologica 2016; 101: 15161523 ©

Frequencies of specific clonal pre-treatment cytogenetic abnormalities in acute myeloid leukemia patients whose karyotype was abnormal or normal at complete remission. Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Pre-treatment clinical characteristics of cytogenetically abnormal acute myeloid leukemia patients whose karyotype was abnormal or normal at complete remission. Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Treatment outcomes of cytogenetically abnormal acute myeloid leukemia patients whose karyotype was abnormal or normal at complete remission. Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Disease-free survival (A) and overall survival (B) of patients with de novo acute myeloid leukemia and abnormal pre-treatment karyotypes according to the presence or absence of chromosome abnormalities at the time of complete remission (CR). Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Treatment outcomes of cytogenetically abnormal acute myeloid leukemia patients according to the presence or absence of any clonal or non-clonal, pre-treatment-related or pre-treatmentunrelated chromosome abnormality or abnormalities at complete remission. Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Disease-free survival (A) and overall survival (B) of patients with de novo acute myeloid leukemia and abnormal pre-treatment karyotypes according to the presence or absence of any chromosome abnormality or abnormalities, both clonal and non-clonal, pre-tre. . . Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation

Multivariable analyses of outcome in cytogenetically abnormal acute myeloid leukemia patients according to the presence or absence of any clonal or non-clonal, pre-treatment-related or pretreatment-unrelated chromosome abnormality or abnormalities at compl. . . Christian Niederwieser et al. Haematologica 2016; 101: 15161523 © 2016 by Ferrata Storti Foundation